The $1 billion deal emphasises that for IP professionals a detailed understanding of data-related issues is set to become essential
The rise of disruptive new technology means that everything you thought you knew about making money from IP is set to change
Services at the FDA could “grind to a halt” in a matter weeks if the budget deadlock between President Trump and Democrats continues. Major disruption at the USPTO and in the courts may also be on the cards.
IAM Market teams up with Richardson Oliver Insights to deliver new tranche of assets to its IP buying, selling, licensing and tech transfer platform being offered by top brokers
An insider’s guide to how it has revolutionised the life sciences patent landscape - and will continue to do so
Supreme Court decision does not bring any clarity to the technical issues at stake, but it does establish clear rules for how judges should handle complex patent suits
A summary of the major IP news from the biotechnology, pharmaceutical and medical technology sectors in November and the first-half of December
The decision in Monsanto’s appeal against the revocation of a key patent right could have profound implications on the ability to protect agro-biotech inventions in India
This year's event in Shanghai has now come to an end. It's been a great couple of days, including the IP Asia Elite Gala Dinner and Awards held last night
How Chinese courts will rule the patent world; Qualcomm's 5G licensing spree; don't jail trolls, says former supreme court judge; patent sales are on the up; plus a whole lot more from a wet, but spectacular, Shanghai Pudong
Your essential Sunday reading: a summary of all the stories posted on the IAM platform in the past week - as well as links to each one
Life sciences IP is on the front line as American consumers, legislators and the Trump administration kick back against the high cost of medicines. Reform campaigners say they have never been more confident of change.
Justices today considering a much-anticipated case whose outcome could make it harder for pharma companies to obtain such protection in the future
Tipped to be the ranking Republican on the House Judiciary Committee, Doug Collins looks set to emerge as one of most powerful IP policy voices on Capitol Hill